Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 15Gynecologic 13Gastrointestinal 13Genitourinary 10Other hematologic neoplasm 9CNS 8Lymphoid 6Dermatologic 6Head & Neck 5Breast 5Sarcoma 4Myeloid 4Endocrine 4NET 3Other neoplasm 2Plasma cell 1Other solid neoplasm 1

Conditions

Advanced Solid Tumor 130Advanced Solid Tumors 122Solid Tumor 101Mesothelioma, Malignant 48Solid Tumors 43Mesothelioma 42Hematopoietic and Lymphatic System Neoplasm 30Solid Tumor, Adult 27Retinoblastoma 20Pancreatic Neoplasms 14Carcinoma, Non-Small-Cell Lung 14Ovarian Neoplasms 13Lung Neoplasms 13Neoplasms 11Advanced Malignant Solid Tumor 11Advanced or Metastatic Solid Tumors 10Solid Tumors, Adult 9Sarcoma 9Hematopoietic and Lymphoid System Neoplasm 9Advanced Malignant Solid Tumors 9Stomach Neoplasms 8Solid Tumor Malignancies 8Neoplasm Metastasis 8Melanoma 8Malignant Solid Tumors 8Malignant Solid Neoplasm 8Locally Advanced or Metastatic Solid Tumors 8Kidney Neoplasms 8Colorectal Neoplasms 8Advanced/Metastatic Solid Tumors 8

Interventions

enzalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Neoplasms by Site × Other solid neoplasm × Clear all
NCT04104776 2025-05-15

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Novartis

Phase 1/2 Recruiting
275 enrolled
GenitourinaryGynecologicLymphoidOther solid neoplasmThoracic

Mesothelioma, Malignant, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Endometrial Neoplasms, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡